Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 3 | 5 | 8 |
| 2008 | 3 | 14 | 17 |
| 2009 | 5 | 3 | 8 |
| 2010 | 8 | 12 | 20 |
| 2011 | 6 | 7 | 13 |
| 2012 | 9 | 6 | 15 |
| 2013 | 8 | 14 | 22 |
| 2014 | 18 | 8 | 26 |
| 2015 | 16 | 5 | 21 |
| 2016 | 20 | 12 | 32 |
| 2017 | 15 | 13 | 28 |
| 2018 | 22 | 6 | 28 |
| 2019 | 14 | 12 | 26 |
| 2020 | 14 | 11 | 25 |
| 2021 | 22 | 12 | 34 |
| 2022 | 2 | 17 | 19 |
| 2023 | 3 | 18 | 21 |
| 2024 | 18 | 7 | 25 |
| 2025 | 27 | 9 | 36 |
| 2026 | 17 | 0 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. Blood Adv. 2026 09 08; 10(17):5821-5827.
-
Therapy-associated lineage plasticity in DIPG following combined CDK4/6 inhibitor, temozolomide, and radiation. Cancer Lett. 2026 Oct 28; 659:218771.
-
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2?-?metastatic breast cancer: a single-institution experience. J Egypt Natl Canc Inst. 2026 Jul 28; 38(1).
-
Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis. Pediatr Blood Cancer. 2026 Sep; 73(9):e70525.
-
Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation. Clin Pharmacokinet. 2026 Sep; 65(9):1389-1403.
-
Tolebrutinib liver safety: A detailed overview. Mult Scler Relat Disord. 2026 Sep; 113:107404.
-
PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation. J Virol. 2026 Aug 18; 100(8):e0050026.
-
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma. Nat Commun. 2026 Jun 26; 17(1).
-
Structural Transformation of a BRAF Inhibitor into a Selective PKR Inhibitor. J Med Chem. 2026 Jul 09; 69(13):15227-15246.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.